1-4 of 4
David Ritchie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study

Clinical Trials & Observations
John Moore, Nada Hamad, David Gottlieb, Ashish Bajel, David Ritchie, David Yeung, Matthew Greenwood, Duncan Purtill, Steven Tran, Annie Solterbeck, Donna Aarons, John Kwan
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5554–5565.
https://doi.org/10.1182/bloodadvances.2023009840
Published: 2023
Includes: Supplemental data
Journal Articles

Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant

Wei Jiang, Leighton E. Clancy, Selmir Avdic, Gaurav Sutrave, Janine Street, Renee Simms, Helen M. McGuire, Ellis Patrick, Adam S. Chan, Georgia McCaughan, Nadav Myers, Kenneth P. Micklethwaite, Vicki Antonenas, Adrian G. Selim, David Ritchie, Caroline M. Bateman, Peter J. Shaw, Emily Blyth, David J. Gottlieb
Journal: Blood Advances
Blood Adv (2022) 6 (17): 4949–4966.
https://doi.org/10.1182/bloodadvances.2022007103
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation

Ashvind Prabahran, Rachel Koldej, Lynette Chee, David Ritchie
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1947–1959.
https://doi.org/10.1182/bloodadvances.2021004537
Published: 2022
Journal Articles

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy

Sara Mastaglio, Eric Wong, Travis Perera, Jane Ripley, Piers Blombery, Mark J. Smyth, Rachel Koldej, David Ritchie
Journal: Blood Advances
Blood Adv (2018) 2 (4): 335–346.
https://doi.org/10.1182/bloodadvances.2017015230
Published: 2018
Includes: Supplemental data